Pretax profits at Irish unit of Regeneron soar 18-fold to $386.47m

Irish company makes treatments for serious medical conditions and manages IP

Regeneron operates from the former Dell site in Limerick. Photograph: iStock

Regeneron operates from the former Dell site in Limerick. Photograph: iStock

 

Pretax profits at an Irish unit of bio-pharma giant Regeneron soared 18-fold to $386.47 million (€347 million) in 2018.

New accounts filed by US-owned Regeneron International Ltd show that the company recorded the sharp increase in pretax profits as revenues jumped by 44 per cent from $1.3 billion to $1.87 billion.

The Regeneron operation here has gone from strength to strength since it established its Irish head office at the former Dell site in Limerick.

The directors for Regeneron International said the increase in the value of its property, plant and equipment from $648 million to $749 million in 2018 was primarily due to renovations and additions to Regeneron’s Limerick facility.

Medical conditions

The main activity of Regeneron International is the development and manufacture of drugs for serious medical conditions and the management of intellectual property.

The directors state that the increase in revenues can be attributed to the company’s share of profits of the commercialisation of eye-treatment drug Eylea outside the US.

The accounts show that $992.36 million of the company’s revenues were attributed to Eylea sales outside the US in 2018.

Numbers employed at the company in 2018 increased from 647 to 850 as staff costs increased from $97.77 million to $130.52 million.

The Dublin-registered company is tax resident in Bermuda and in 2018 received a tax benefit of $806.49 million, resulting in a post-tax profit of €1.1 billion.